KAT-II Inhibitor

Kynexis Completes Phase 2 Enrollment for KYN-5356 in Cognitive Impairment

Naarden, The Netherlands, August 19, 2026 Kynexis, a clinical-stage biotechnology company developing therapies for cognitive disorders, has raised an...

By cGxPwire Editor
August 20, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

KAT-II Inhibitor

Kynexis Completes Phase 2 Enrollment for KYN-5356 in Cognitive Impairment